CLINICAL LABORATORY, cilt.59, sa.1-2, ss.71-77, 2013 (SCI-Expanded)
Background: Omalizumab, a recombinant humanized monoclonal antibody to IgE, is recommended as a new option for the treatment of severe persistent allergic asthma. The purpose of this study is to assess the effects omalizumab treatment on life quality and its side effects in severe persistent asthma patients.